



AMD is the leading cause of blindness in the developed world for people over 50

AlphaRET

AlphaRET Pty Ltd is a wholly owned subsidiary of Nova Eye Medical Limited (ASX:EYE) and was established to progress the development of 2RT®


2RT Pivotal Study and Regulatory Pathway

May 2022


alpha-ret.com

Disclaimer


This presentation has been prepared by Nova Eye Medical Limited (ASX: EYE). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to the accuracy, adequacy or reliability of any statement, estimates, opinions or other information contained in the presentation. This presentation may contain forward looking statements. These forward-looking statements have been made based upon Nova Eye Medical's expectations and beliefs concerning future developments and their potential effect on Nova Eye Medicals (and its controlled entities) and are subject to risks and uncertainty which are, in many instances, beyond Nova Eye Medical's control. No assurance is given that future developments will be in accordance with Nova Eye Medical's expectations. Actual results could differ materially from those expected by Nova Eye Medical. This presentation does not constitute an offer to sell or a solicitation or an offer to purchase any security or financial product or service. Any such offer or solicitation shall be made only pursuant to a Product Disclosure Statement, Information Memorandum, Prospectus or other offer document relating to a financial product or service. Past performance is not necessarily indicative of future results and no person guarantees the performance of any financial product or service or the amount or timing of any return from it. There can be no assurance that the financial product or service will achieve any targeted return, that asset allocations will be met or that the financial product or service will be able to implement its investment strategy and investment approach or achieve its investment objective. The information contained in this presentation is not intended to be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs.



Age-Related Macular Degeneration



Normal Vision



Macular Degeneration

2RT® - Subthreshold Nanosecond Laser


2RT® is a rejuvenative retinal laser therapy that utilizes a nanosecond laser pulse and unique pixelated laser beam profile

“Based on the LEAD study outcomes, 2RT® is currently a leading candidate treatment in the world for slowing the progression of patients with intermediate AMD to either late stage Wet or Dry AMD.”

(Identified by Edison Group in its publication “Saving the sight of millions, Blindness: the underrated business case” September 2020 - <https://bit.ly/EdisonAMD>).

LEAD study - LEAD (Laser Intervention in Early sage Age related macular Degeneration), 292-person study conducted from 2012-2018 with follow up through to 2020

2RT[®] for intervention in AMD progression



Intervention concept schematic based on a *post hoc* analysis reported within “Subthreshold Nanosecond Laser Intervention in Age-Related Macular Degeneration - The LEAD Randomized Controlled Clinical Trial” Robyn H. Guymer, MBBS, PhD, et al and published in peer reviewed journal *Ophthalmology* of the American Academy of Ophthalmology

This post hoc analysis found that the 77% reduction in the rate of progression occurred in patients who did not have reticular pseudodrusen (RPD) at enrolment. 24% of the study population had RPD at enrolment.

Pivotal Clinical Study to address USA and Europe



AlphaRET's recent communications with the FDA has provided guidance on the clinical study plan and a subsequent regulatory pathway for a clearance to market 2RT® in the USA for the treatment of patients with iAMD, and who do not have RPD, to delay progression to vision threatening, late-stage AMD.

Two protocols have been defined for the pivotal clinical study:

Protocol A

a fast-track protocol for patients with iAMD and without RPD at a higher risk of progression

- 4 treatments over 24 months with approx. 250 patients
- Aiming to build on clinical signal in LEAD Study

- The protocols will be conducted concurrently
- Protocol A will provide an earlier study outcome than Protocol B

Protocol B

a more extensive protocol for general iAMD without RPD patients

- 6 treatments over 36 months with approx. 500 patients
- Aiming to confirm results of the LEAD study post hoc analysis

- The concurrent execution of both Protocol A and Protocol B will enable the Company to harvest data across the broader range of indications possible
- Provides greater scope for a successful study outcome

2RT[®] Roadmap Pivotal Study



PRE-CLINICAL WORK

PILOT CLINICAL TRIAL

CE MARK (iAMD) APPROVED FOR SALE IN AUST, NZ & EUROPE

EFFICACY & SAFETY DEMONSTRATION CLINICAL STUDY (“LEAD”)

PROTOCOL PREPARATION FOR PIVOTAL STUDY TO CONFIRM LEAD

USA FDA FEEDBACK RECEIVED

ENGAGE WITH POTENTIAL PARTNERS AND FUNDING SOURCES

CONFIRMATORY PIVOTAL CLINICAL STUDY

Global Retinal Experts Support



Principal Investigator Professor Robyn Guymer, AM MBBS, PhD

“I am pleased to be a part of this follow up study. 2RT[®] addresses the disease in its earlier stages. No other device or pharmaceutical in the world does this. Like all chronic disease, early detection and treatment is vital to prevent complications and the ensuing burden on health care systems, and patients and their families. The LEAD study was very encouraging but was not conclusive. I look forward to starting this work, providing additional information to the FDA and then a successful study outcome.”

Dr. Philip Rosenfeld, Professor of Ophthalmology at the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine in Miami

“The LEAD Study completed by Professor Guymer was a well-controlled clinical trial that showed the immense potential of 2RT[®]. However, a second study is required. If the second study is successful, AlphaRET will have the data needed to harness that potential and significantly change the landscape in AMD therapy in the USA and around the world. It is not unusual that the FDA is taking such a cautious approach and requesting additional data prior to establishing investigator sites in the USA. In fact, I am pleased that we now have a clear understanding of what is needed by the FDA to move 2RT[®] forward in the USA.”

Estimated Revenue Opportunity for 2RT[®]



Subject to the completion of a pivotal study or similar to confirm results of the LEAD study (77% reduction in rate of progression to late-stage AMD in select patients with iAMD) the opportunity is very large.




Business model comprising of capital equipment sale and procedure fee has corollary with laser vision correction technology, which was launched in the US in the early 2000s by start-up companies.

¹Marketscope 2018 Ophthalmic Laser Report. ² Guymer et al "Subthreshold Nano Second Laser Intervention in Age Related Macular Degeneration – The LEAD Randomised Controlled Clinical Trial". ³AlphaRET estimate. ⁴ AlphaRET estimate based on 'Marketscore 2018 Ophthalmic Laser Report "for USA, Europe and Other Developed Nations by Company.

Program milestones

Program milestones are set out below:



AlphaRET

alpha-ret.com

Tom Spurling

Managing Director

W: +61 8 8362 0193

E: tspurling@nova-eye.com

Mark Flynn

Investor Relations

M: +61 416 068 733

E: mflynn@nova-eye.com